We are live on ! Find out more
IGMS

IGM Biosciences
IGMS

Delisted

IGMS was delisted on the 13th of August, 2025.

Back to rankings

79 hedge funds and large institutions have $186M invested in IGM Biosciences in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,511% more call options, than puts

Call options by funds: $145K | Put options by funds: $9K

29% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 21

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0% more funds holding

Funds holding: 79 → 79 (0)

3.66% less ownership

Funds ownership: 71.55% → 67.89% (-3.7%)

10% less capital invested

Capital invested by funds: $208M → $186M (-$21.3M)

Holders
79
Holders Change
–
Holders Change %
0%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
27
Reduced
21
Closed
14
Calls
$145K
Puts
$9K
Net Calls
+$136K
Net Calls Change
+$76K

Top Buyers

Rank Fund Capital Flow
1
ECM
ExodusPoint Capital Management
New York
+$3.85M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.72M
3
OM
Opaleye Management
Massachusetts
+$1.68M
4
First Manhattan
First Manhattan
New York
+$1.46M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$1.05M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$4.02M
2
Millennium Management
Millennium Management
New York
-$1.84M
3
Goldman Sachs
Goldman Sachs
New York
-$1.83M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$846K
5
Renaissance Technologies
Renaissance Technologies
New York
-$722K
Name Holding Trade Value Shares
Change 		Change in
Stake
Nisa Investment Advisors
76
Nisa Investment Advisors
Missouri
$443 +$450 +53 New
Toronto Dominion Bank
77
Toronto Dominion Bank
Ontario, Canada
$284 – – –
S
78
SignatureFD
Georgia
$251 -$2.3K -271 -90%
US Bancorp
79
US Bancorp
Minnesota
$142 -$3.23K -381 -96%
Walleye Capital
80
Walleye Capital
New York
– -$641K -69,417 Closed
Susquehanna International Group
81
Susquehanna International Group
Pennsylvania
– -$387K -41,941 Closed
Squarepoint
82
Squarepoint
New York
– -$243K -26,312 Closed
MS
83
Maven Securities
Jersey
– -$229K -24,800 Closed
TI
84
Trexquant Investment
Connecticut
– -$216K -23,387 Closed
JF
85
Jump Financial
Illinois
– -$183K -19,783 Closed
Verition Fund Management
86
Verition Fund Management
Connecticut
– -$160K -17,306 Closed
HF
87
HRT Financial
New York
– -$140K -15,257 Closed
EGM
88
Engineers Gate Manager
New York
– -$136K -14,734 Closed
Prudential Financial
89
Prudential Financial
New Jersey
– -$111K -12,070 Closed
Invesco
90
Invesco
Georgia
– -$104K -11,312 Closed
CS
91
Credit Suisse
Switzerland
– -$97.9K -10,607 Closed
CSS
92
Cubist Systematic Strategies
Connecticut
– -$96.9K -10,500 Closed
Deutsche Bank
93
Deutsche Bank
Germany
– -$45.8K -4,965 Closed
1 2 3
4

IGMS Hedge Fund Activity: Q3 2023 in Review

79 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q3 2023, worth a combined $186M — down 10% from $208M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new IGMS positions and 14 closed out — a net gain of 1 holder — while 27 added to existing stakes and 21 trimmed.

The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $3.85M. The largest seller was UBS AM, cutting an estimated $4.02M.

  • 79 institutional investors held IGM Biosciences (IGMS) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $186M of IGM Biosciences stock for Q3 2023, down 10% quarter-over-quarter.
  • 15 funds opened new IGM Biosciences positions in Q3 2023 and 14 closed out, a net change of +1 holder.
  • The largest IGM Biosciences buyer in Q3 2023 was ExodusPoint Capital Management, an estimated $3.85M added.
  • The largest IGM Biosciences seller in Q3 2023 was UBS AM, an estimated $4.02M sold.

Based on aggregated 13F filings for Q3 2023.